{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:15:15Z","timestamp":1791918915512,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T00:00:00Z","timestamp":1644019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010909","name":"Young Scientists Fund","doi-asserted-by":"publisher","award":["81600436"],"award-info":[{"award-number":["81600436"]}],"id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adrenocortical carcinoma (ACC) is an aggressive and rare malignant tumor and is prone to local invasion and metastasis. And, overexpressed Centromere Protein F (CENPF) is closely related to the oncogenesis of various neoplasms, including ACC. However, the prognosis and exact biological function of CENPF in ACC remains largely unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the present essay, the expression patterns and prognostic value of CENPF in ACC were investigated in clinical specimens and public cancer databases, including GEO and TCGA. The potential signaling mechanism of CENPF in ACC was studied based on gene-set enrichment analysis (GSEA). Furthermore, a small RNA interference experiment was conducted to probe the underlying biological function of CENPF in the human ACC cell line, SW13 cells. Lastly, two available therapeutic strategies, including immunotherapy and chemotherapy, have been further explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The expression of CENPF in human ACC samples, GEO, and TCGA databases depicted that CENPF was overtly hyper-expressed in ACC patients and positively correlated with tumor stage. The aberrant expression of CENPF was significantly correlated with unfavorable overall survival (OS) in ACC patients. Then, the GSEA analysis declared that CENPF was mainly involved in the G2\/M-phase mediated cell cycle and p53 signaling pathway. Further, the in vitro experiment demonstrated that the interaction between CENPF and CDK1 augmented the G2\/M-phase transition of mitosis, cell proliferation and might induce p53 mediated anti-tumor effect in human ACC cell line, SW13 cells. Lastly, immune infiltration analysis highlighted that ACC patients with high CENPF expression harbored significantly different immune cell populations, and high TMB\/MSI score. The gene-drug interaction network stated that CENPF inhibitors, such as Cisplatin, Sunitinib, and Etoposide, might serve as potential drugs for the therapy of ACC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The result points out that CENPF is significantly overexpressed in ACC patients. The overexpressed CENPF predicts a poor prognosis of ACC and might augment the progress of ACC. Thus, CENPF and related genes might serve as a novel prognostic biomarker or latent therapeutic target for ACC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-022-03277-y","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T08:03:03Z","timestamp":1644048183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["CENPF\/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2\/M-phase cell cycle"],"prefix":"10.1186","volume":"20","author":[{"given":"Yu-gang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-min","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-1178","authenticated-orcid":false,"given":"Xian-bin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,5]]},"reference":[{"key":"3277_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","volume":"15","author":"J Crona","year":"2019","unstructured":"Crona J, Beuschlein F. Adrenocortical carcinoma\u2014towards genomics guided clinical care. Nat Rev Endocrinol. 2019;15:548\u201360.","journal-title":"Nat Rev Endocrinol"},{"key":"3277_CR2","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/cncr.32802","volume":"126","author":"SJ Henley","year":"2020","unstructured":"Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2020;126:2225\u201349.","journal-title":"Cancer"},{"key":"3277_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","volume":"30","author":"E Kebebew","year":"2006","unstructured":"Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872\u20138.","journal-title":"World J Surg"},{"key":"3277_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:243\u201350.","journal-title":"Cancer"},{"key":"3277_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12920-020-00809-7","volume":"13","author":"T Fojo","year":"2020","unstructured":"Fojo T, Huff L, Litman T, Im K, Edgerly M, Del Rivero J, et al. Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape. BMC Med Genomics. 2020;13:165\u201379.","journal-title":"BMC Med Genomics"},{"key":"3277_CR6","doi-asserted-by":"publisher","first-page":"E476","DOI":"10.1210\/jc.2011-1982","volume":"97","author":"LJ Herrmann","year":"2012","unstructured":"Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N, et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97:E476\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"3277_CR7","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1038\/ncomms7302","volume":"6","author":"EM Pinto","year":"2015","unstructured":"Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, Pounds S, et al. Genomic landscape of paediatric adrenocortical tumours. Nat Commun. 2015;6:6302\u201311.","journal-title":"Nat Commun"},{"key":"3277_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723\u201336.","journal-title":"Cancer Cell"},{"key":"3277_CR9","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1210\/en.2015-1367","volume":"156","author":"S Sbiera","year":"2015","unstructured":"Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, et al. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156:3895\u2013908.","journal-title":"Endocrinology"},{"key":"3277_CR10","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","volume":"65","author":"F Tissier","year":"2005","unstructured":"Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagner\u00e9 AM, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65:7622\u20137.","journal-title":"Cancer Res"},{"key":"3277_CR11","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1210\/jc.2018-01348","volume":"103","author":"J Lippert","year":"2018","unstructured":"Lippert J, Appenzeller S, Liang R, Sbiera S, Kircher S, Altieri B, et al. Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018;103:4511\u201323.","journal-title":"J Clin Endocrinol Metab"},{"key":"3277_CR12","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.","journal-title":"N Engl J Med"},{"key":"3277_CR13","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-18-2693","volume":"25","author":"DR Mohan","year":"2019","unstructured":"Mohan DR, Lerario AM, Else T, Mukherjee B, Almeida MQ, Vinco M, et al. Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. Clin Cancer Res. 2019;25:3276\u201388.","journal-title":"Clin Cancer Res"},{"key":"3277_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/scitranslmed.aac8228","volume":"8","author":"C Koschmann","year":"2016","unstructured":"Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med. 2016;8:328\u201347.","journal-title":"Sci Transl Med"},{"key":"3277_CR15","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/ijms22031238","volume":"22","author":"VB Brondani","year":"2021","unstructured":"Brondani VB, Lacombe AMF, Mariani BMP, Montenegro L, Soares IC, Bezerra-Neto JE, et al. Low protein expression of both ATRX and ZNRF3 as novel negative prognostic markers of adult adrenocortical carcinoma. Int J Mol Sci. 2021;22:1238\u201356.","journal-title":"Int J Mol Sci"},{"key":"3277_CR16","doi-asserted-by":"publisher","first-page":"E493","DOI":"10.1210\/jc.2014-3282","volume":"100","author":"CC Juhlin","year":"2015","unstructured":"Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab. 2015;100:E493-502.","journal-title":"J Clin Endocrinol Metab"},{"key":"3277_CR17","first-page":"1675","volume":"42","author":"F Svahn","year":"2018","unstructured":"Svahn F, Paulsson JO, Stenman A, Fotouhi O, Mu N, Murtha TD, et al. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma. Int J Mol Med. 2018;42:1675\u201383.","journal-title":"Int J Mol Med"},{"key":"3277_CR18","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1373\/clinchem.2017.277624","volume":"63","author":"DR Taylor","year":"2017","unstructured":"Taylor DR, Ghataore L, Couchman L, Vincent RP, Whitelaw B, Lewis D, et al. A 13-steroid serum panel based on LC-MS\/MS: use in detection of adrenocortical carcinoma. Clin Chem. 2017;63:1836\u201346.","journal-title":"Clin Chem"},{"key":"3277_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.bbrc.2013.06.021","volume":"436","author":"Y Dai","year":"2013","unstructured":"Dai Y, Liu L, Zeng T, Zhu YH, Li J, Chen L, et al. Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma. Biochem Biophys Res Commun. 2013;436:711\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"3277_CR20","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/cas.14037","volume":"110","author":"X Yang","year":"2019","unstructured":"Yang X, Miao BS, Wei CY, Dong RZ, Gao PT, Zhang XY, et al. Lymphoid-specific helicase promotes the growth and invasion of hepatocellular carcinoma by transcriptional regulation of centromere protein F expression. Cancer Sci. 2019;110:2133\u201344.","journal-title":"Cancer Sci"},{"key":"3277_CR21","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.7150\/jca.52187","volume":"12","author":"Y Huang","year":"2021","unstructured":"Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere protein F ( CENPF ) serves as a potential prognostic biomarker and target for human hepatocellular carcinoma. J Cancer. 2021;12:2933\u201351.","journal-title":"J Cancer"},{"key":"3277_CR22","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1080\/15384101.2018.1557496","volume":"17","author":"M Shahid","year":"2018","unstructured":"Shahid M, Lee MY, Piplani H, Andres AM, Zhou B, Yeon A, et al. Centromere protein F (CENPF), a microtubule binding protein, modulates cancer metabolism by regulating pyruvate kinase M2 phosphorylation signaling. Cell Cycle. 2018;17:2802\u201318.","journal-title":"Cell Cycle"},{"key":"3277_CR23","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12935-019-0986-8","volume":"19","author":"J Sun","year":"2019","unstructured":"Sun J, Huang J, Lan J, Zhou K, Gao Y, Song Z, et al. Overexpression of CENPF correlates with poor prognosis and tumor bone metastasis in breast cancer. Cancer Cell Int. 2019;19:264\u201374.","journal-title":"Cancer Cell Int"},{"key":"3277_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s00412-005-0046-0","volume":"115","author":"A Varis","year":"2006","unstructured":"Varis A, Salmela AL, Kallio MJ. Cenp-F (mitosin) is more than a mitotic marker. Chromosoma. 2006;115:288\u201395.","journal-title":"Chromosoma"},{"key":"3277_CR25","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccr.2014.03.017","volume":"25","author":"A Aytes","year":"2014","unstructured":"Aytes A, Mitrofanova A, Lefebvre C, Alvarez MJ, Castillo-Martin M, Zheng T, et al. Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. Cancer Cell. 2014;25:638\u201351.","journal-title":"Cancer Cell"},{"key":"3277_CR26","doi-asserted-by":"publisher","first-page":"11418","DOI":"10.1038\/ncomms11418","volume":"7","author":"SC Lin","year":"2016","unstructured":"Lin SC, Kao CY, Lee HJ, Creighton CJ, Ittmann MM, Tsai SJ, et al. Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nat Commun. 2016;7:11418\u201331.","journal-title":"Nat Commun"},{"key":"3277_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-59745-551-0_1","volume":"671","author":"SC Sealfon","year":"2011","unstructured":"Sealfon SC, Chu TT. RNA and DNA microarrays. Methods Mol Biol. 2011;671:3\u201334.","journal-title":"Methods Mol Biol"},{"key":"3277_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:47\u201359.","journal-title":"Nucleic Acids Res"},{"key":"3277_CR29","doi-asserted-by":"publisher","first-page":"4892","DOI":"10.7150\/jca.32768","volume":"10","author":"J Shi","year":"2019","unstructured":"Shi J, Chen L, Chen Y, Lu Y, Chen X, Yang Z. Aldo-keto reductase family 1 member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma. J Cancer. 2019;10:4892\u2013901.","journal-title":"J Cancer"},{"key":"3277_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:98\u2013102.","journal-title":"Nucleic Acids Res"},{"key":"3277_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12935-020-1113-6","volume":"20","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Lin E, Zhuang H, Xie L, Feng X, Liu J, et al. Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma. Cancer Cell Int. 2020;20:27\u201344.","journal-title":"Cancer Cell Int"},{"key":"3277_CR32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3389\/fonc.2020.00796","volume":"10","author":"W Lin","year":"2020","unstructured":"Lin W, Wu S, Chen X, Ye Y, Weng Y, Pan Y, et al. Characterization of hypoxia signature to evaluate the tumor immune microenvironment and predict prognosis in glioma groups. Front Oncol. 2020;10:796.","journal-title":"Front Oncol"},{"key":"3277_CR33","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1158\/2326-6066.CIR-18-0436","volume":"7","author":"D Zeng","year":"2019","unstructured":"Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7:737\u201350.","journal-title":"Cancer Immunol Res"},{"key":"3277_CR34","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1111\/jcmm.14918","volume":"24","author":"Y Xiong","year":"2020","unstructured":"Xiong Y, Yuan L, Xiong J, Xu H, Luo Y, Wang G, et al. An outcome model for human bladder cancer: a comprehensive study based on weighted gene co-expression network analysis. J Cell Mol Med. 2020;24:2342\u201355.","journal-title":"J Cell Mol Med"},{"key":"3277_CR35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejso.2019.09.143","volume":"46","author":"SH Jeong","year":"2020","unstructured":"Jeong SH, Kim RB, Park SY, Park J, Jung EJ, Ju YT, et al. Nomogram for predicting gastric cancer recurrence using biomarker gene expression. Eur J Surg Oncol. 2020;46:195\u2013201.","journal-title":"Eur J Surg Oncol"},{"key":"3277_CR36","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci"},{"key":"3277_CR37","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/ng1180","volume":"34","author":"VK Mootha","year":"2003","unstructured":"Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, et al. PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267\u201373.","journal-title":"Nat Genet"},{"key":"3277_CR38","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pag\u00e8s C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960\u20134.","journal-title":"Science"},{"key":"3277_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773\u201382.","journal-title":"Nat Biotechnol"},{"key":"3277_CR40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/path.5468","volume":"251","author":"F Wu","year":"2020","unstructured":"Wu F, Li GZ, Liu HJ, Zhao Z, Chai RC, Liu YQ, et al. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma. J Pathol. 2020;251:272\u201383.","journal-title":"J Pathol"},{"key":"3277_CR41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The immune landscape of cancer. Immunity. 2018;48:799\u2013811.","journal-title":"Immunity"},{"key":"3277_CR42","doi-asserted-by":"publisher","first-page":"D948","DOI":"10.1093\/nar\/gky868","volume":"47","author":"AP Davis","year":"2019","unstructured":"Davis AP, Grondin CJ, Johnson RJ, Sciaky D, McMorran R, Wiegers J, et al. The comparative toxicogenomics database: update 2019. Nucleic Acids Res. 2019;47:D948\u201354.","journal-title":"Nucleic Acids Res"},{"key":"3277_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025991","volume":"6","author":"WC Reinhold","year":"2011","unstructured":"Reinhold WC, Erliandri I, Liu H, Zoppoli G, Pommier Y, Larionov V. Identification of a predominant co-regulation among kinetochore genes, prospective regulatory elements, and association with genomic instability. PLoS ONE. 2011;6: e25991.","journal-title":"PLoS ONE"},{"key":"3277_CR44","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.molcel.2019.04.010","volume":"74","author":"L Clijsters","year":"2019","unstructured":"Clijsters L, Hoencamp C, Calis JJA, Marzio A, Handgraaf SM, Cuitino MC, et al. Cyclin F controls cell-cycle transcriptional outputs by directing the degradation of the three activator E2Fs. Mol Cell. 2019;74:1264\u201377.","journal-title":"Mol Cell"},{"key":"3277_CR45","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/jcp.25988","volume":"233","author":"Q Chen","year":"2018","unstructured":"Chen Q, Wang L, Jiang M, Huang J, Jiang Z, Feng H, et al. E2F1 interactive with BRCA1 pathway induces HCC two different small molecule metabolism or cell cycle regulation via mitochondrion or CD4+T to cytosol. J Cell Physiol. 2018;233:1213\u201321.","journal-title":"J Cell Physiol"},{"key":"3277_CR46","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1242\/jcs.115.17.3403","volume":"115","author":"D Hussein","year":"2002","unstructured":"Hussein D, Taylor SS. Farnesylation of Cenp-F is required for G2\/M progression and degradation after mitosis. J Cell Sci. 2002;115:3403\u201314.","journal-title":"J Cell Sci"},{"key":"3277_CR47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1089\/cmb.2017.0056","volume":"24","author":"T Ma","year":"2017","unstructured":"Ma T, Liang F, Oesterreich S, Tseng GC. A joint bayesian model for integrating microarray and RNA sequencing transcriptomic data. J Comput Biol. 2017;24:647\u201362.","journal-title":"J Comput Biol"},{"key":"3277_CR48","doi-asserted-by":"publisher","first-page":"43223","DOI":"10.1371\/journal.pone.0043223","volume":"7","author":"HE Kim","year":"2012","unstructured":"Kim HE, Kim DG, Lee KJ, Son JG, Song MY, Park YM, et al. Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS ONE. 2012;7:43223\u201335.","journal-title":"PLoS ONE"},{"key":"3277_CR49","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1111\/j.1349-7006.2009.01150.x","volume":"100","author":"K Kojima","year":"2009","unstructured":"Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci. 2009;100:1128\u201336.","journal-title":"Cancer Sci"},{"key":"3277_CR50","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/jcmm.14878","volume":"24","author":"S Chen","year":"2020","unstructured":"Chen S, Zhou Q, Guo Z, Wang Y, Wang L, Liu X, et al. Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1\/S cell cycle arrest via the ATM\/CHK2\/p53 pathway. J Cell Mol Med. 2020;24:1804\u201321.","journal-title":"J Cell Mol Med"},{"key":"3277_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012341","volume":"5","author":"D Nantajit","year":"2010","unstructured":"Nantajit D, Fan M, Duru N, Wen Y, Reed JC, Li JJ. Cyclin B1\/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response. PLoS ONE. 2010;5: e12341.","journal-title":"PLoS ONE"},{"key":"3277_CR52","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","volume":"31","author":"LT Chen","year":"2020","unstructured":"Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO MOS and SSO. Ann Oncol. 2020;31:334\u201351.","journal-title":"Ann Oncol"},{"key":"3277_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2018.11.019","volume":"443","author":"B Xie","year":"2019","unstructured":"Xie B, Wang S, Jiang N, Li JJ. Cyclin B1\/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance. Cancer Lett. 2019;443:56\u201366.","journal-title":"Cancer Lett"},{"key":"3277_CR54","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.canlet.2019.05.036","volume":"459","author":"L Fang","year":"2019","unstructured":"Fang L, Du WW, Awan FM, Dong J, Yang BB. The circular RNA circ-Ccnb1 dissociates Ccnb1\/Cdk1 complex suppressing cell invasion and tumorigenesis. Cancer Lett. 2019;459:216\u201326.","journal-title":"Cancer Lett"},{"key":"3277_CR55","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/cancers12020491","volume":"12","author":"M Dimri","year":"2020","unstructured":"Dimri M, Satyanarayana A. Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. Cancers. 2020;12:491\u2013509.","journal-title":"Cancers"},{"key":"3277_CR56","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03277-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-022-03277-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-022-03277-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T08:10:18Z","timestamp":1666599018000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-022-03277-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3277"],"URL":"https:\/\/doi.org\/10.1186\/s12967-022-03277-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1012618\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,5]]},"assertion":[{"value":"24 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All clinical specimens were collected by informed consent (IFC) from patients or family members, and this study has been supported and approved by the Ethics Committee of Taihe Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}